MedPath

A study to compare the effectiveness of intravenous oxytocin with intramuscular oxytocin given at the third stage of labour at preventing bleeding at vaginal birth

Not Applicable
Completed
Conditions
Postpartum haemorrhage following vaginal delivery
Pregnancy and Childbirth
Registration Number
ISRCTN14718882
Lead Sponsor
Coombe Women and Infants University Hospital
Brief Summary

2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/29141679 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30181338 [added 20/03/2019]

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
1000
Inclusion Criteria

1. Aged 18 or over
2. Female participants only
3. Singleton pregnancy at more than 36 weeks gestation
4. Those anticipated to have a vaginal delivery

Exclusion Criteria

1. Women who opted for physiological management of the third stage of labour
2. Those who have an antenatal decision for 40IU oxytocin infusion prophylactically following a vaginal delivery
3. Those whom the clinician has a preferred route of administering prophylactic oxytocin for the third stage of labour
4. Those who are deemed to be at risk of postpartum haemorrhage - Previous history of atonic primary postpartum haemorrhage, multiple fibroids, coagulation disorders, thrombocytopenia and receiving anticoagulants
5. Those with previous cardiovascular disorder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of primary postpartum haemorrhage (> 500ml) following intramuscular oxytocin compared with intravenous oxytocin is determined by reviewing participant’s medical notes and data collected in a case report form (CRF) 24 hours post-delivery.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath